XNAS
TVGN
Market cap228mUSD
Jul 09, Last price
1.24USD
1D
1.64%
1Q
24.00%
IPO
-87.60%
Name
Tevogen Bio Holdings Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-14m
L+20,289.72%
CFO
-12m
L+771.78%
Profile
Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY |
|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | |
| Income | ||||
Revenues | ||||
Cost of revenue | 53,564 | 2,274 | 6,727 | |
Unusual Expense (Income) | ||||
NOPBT | (53,564) | (2,274) | (6,727) | |
NOPBT Margin | ||||
Operating Taxes | (231) | |||
Tax Rate | ||||
NOPAT | (53,564) | (2,274) | (6,497) | |
Net income | (13,727) 20,289.72% | (67) -101.53% | 4,408 -128.26% | |
Dividends | ||||
Dividend yield | ||||
Proceeds from repurchase of equity | 2,000 | (342,984) | ||
BB yield | -1.32% | |||
| Debt | ||||
Debt current | 1,880 | 1,632 | 278 | |
Long-term debt | 246 | 722 | 40,441 | |
Deferred revenue | ||||
Other long-term liabilities | 1,081 | 14,494 | (25,022) | |
Net debt | 844 | (14,336) | (316,274) | |
| Cash flow | ||||
Cash from operating activities | (11,999) | (1,376) | (215) | |
CAPEX | (479) | |||
Cash from investing activities | 342,917 | |||
Cash from financing activities | 12,229 | (341,661) | 8 | |
FCF | (50,304) | 122 | (7,734) | |
| Balance | ||||
Cash | 1,283 | 9 | 129 | |
Long term investments | 16,681 | 356,864 | ||
Excess cash | 1,283 | 16,690 | 356,993 | |
Stockholders' equity | (110,567) | (696) | 342,081 | |
Invested Capital | 106,866 | 16,361 | 14,985 | |
ROIC | ||||
ROCE | 1,447.31% | |||
| EV | ||||
Common stock shares outstanding | 146,673 | 165,421 | 120,000 | |
Price | 1.03 | |||
Market cap | 151,073 | |||
EV | 154,716 | |||
EBITDA | (53,161) | (2,274) | (6,497) | |
EV/EBITDA | ||||
Interest | 184 | 256 | ||
Interest/NOPBT | ||||